symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CODX,1.1,-0.515905,116017,33867790,0,0.975-3.84,0.02,"Co-Diagnostics, Inc.",USD,0001692415,US1897631057,189763105,NASDAQ Capital Market,NASDAQ,Medical Devices,https://www.codiagnostics.com,"Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.",Mr. Dwight H. Egan,Healthcare,US,145,801 438 1036,2401 South Foothill Drive,Salt Lake City,UT,84109,3.43309,6.32309,https://financialmodelingprep.com/image-stock/CODX.png,2017-07-12,False,False,True,False,False
